Finanzas: AstraZeneca completes sale of antibiotics business to Pfizer


Pfizer (NYSE:PFE) has completed the acquisition of AstraZeneca’s (NYSE:AZN) antibiotics business, primarily outside the U.S., for an upfront payment of $550M.

LEA TAMBIÉN: Finanzas: Hershey hire spins the wheels on M&A speculation


The drugmaker will then pay another $175M for the unit in January 2019, up to $250M in commercial, regulatory and manufacturing milestones, and up to $600M for sales-related payments and recurring royalties.

Fuente: Seeking Alpha

Reciba las últimas noticias de la industria en su casilla:

Suscribirse ✉


Please enter your comment!
Please enter your name here